Frontiers | A Review of the Therapeutic Potential of Recently Developed G Protein-Biased Kappa Agonists
Antagonists of the kappa opioid receptor - ScienceDirect
New Kappa-Opioid Receptor Agonist Curbs Pain, Avoids Side Effects
Frontiers | The Kappa Opioid Receptor: From Addiction to Depression, and Back
Topical administration of the kappa opioid receptor agonist nalfurafine suppresses corneal neovascularization and inflammation | Scientific Reports
κ-opioid receptor - Wikipedia
Human native kappa opioid receptor functions not predicted by recombinant receptors: Implications for drug design | Scientific Reports
Untangling the complexity of opioid receptor function | Neuropsychopharmacology
Signaling Properties of Structurally Diverse Kappa Opioid Receptor Ligands: Toward in Vitro Models of in Vivo Responses | ACS Chemical Neuroscience
Frontiers | The Kappa Opioid Receptor: From Addiction to Depression, and Back
κ-opioid receptor - Wikipedia
New Kappa-Opioid Receptor Agonist Curbs Pain, Avoids Side Effects
BRL 52537 hydrochloride, kappa-opioid agonist (CAS 112282-24-3) (ab120669)
Opioid Receptor | kappa, mu Opioid Receptor
Structure-Based Discovery of New Antagonist and Biased Agonist Chemotypes for the Kappa Opioid Receptor | Journal of Medicinal Chemistry
Innovation – Cara Therapeutics
A Kappa Opioid Receptor Agonist Blocks Bone Cancer Pain Without Altering Bone Loss, Tumor Size, or Cancer Cell Proliferation in a Mouse Model of Cancer-Induced Bone Pain - The Journal of Pain
Effects of Kappa Opioid Agonists on Cocaine- and Food-Maintained Responding by Rhesus Monkeys | Journal of Pharmacology and Experimental Therapeutics
Mu Agonist Opioids and Kappa Opioids | Download Table
The Role of Dynorphin and the Kappa Opioid Receptor in the Symptomatology of Schizophrenia: A Review of the Evidence - Biological Psychiatry
New Kappa-Opioid Receptor Agonist Curbs Pain, Avoids Side Effects
Pharmaceuticals | Free Full-Text | Therapeutic Potential of Kappa Opioid Agonists | HTML
κ-Opioid Receptor (KOP) | 7TM Antibodies
Opioids in cancer: The κ‑opioid receptor (Review)
